Live Analyst Rating Changes 24522 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Oliver McCammon
LIFE

Oliver McCammon

LifeSci Capital
Wall Street Analyst
★★★☆☆
#1731
on 13Foresight · ranked by our own returns
62%
Success Rate
+2.8%
Average Return
10 of 16 calls profitable · +0.4% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 62% of Oliver McCammon's ratings turned a profit when each position was held for 1 year — averaging +2.8% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

58 Buy 0 Hold 0 Sell
Oliver's Stock Coverage 8 ratings · 2026-08-14
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
AURA
Aura Biosciences Inc
 Aug 12, 2026 BUY Strong Buy
+164.4% avg upside
9 analysts
$23.00
200.71% Upside
 -1.3% ·
CATX
Perspective Therapeutics
 Aug 11, 2026 BUY Strong Buy
+257.2% avg upside
22 analysts
$15.00
383.89% Upside
 +0.3% ·
CRBP
Corbus Pharmaceuticals
 Aug 07, 2026 BUY Strong Buy
+256.8% avg upside
20 analysts
$38.00
277.02% Upside
 +0.3% ·
JANX
Janux Therapeutics Inc
 Aug 07, 2026 BUY Strong Buy
+190.1% avg upside
21 analysts
$60.00
275.00% Upside
 +0.6% ·
GLUE
Monte Rosa Therapeutics
 Aug 06, 2026 BUY Strong Buy
+40.2% avg upside
15 analysts
 — -0.6% ·
CELC
Celcuity
 Jul 15, 2026 BUY Strong Buy
+40.4% avg upside
16 analysts
$165.00
90.57% Upside
 +0.6% ·
CADL
Candel Therapeutics
 May 16, 2026 BUY Strong Buy
+55.7% avg upside
11 analysts
$16.00
35.67% Upside
 +49.2% ·
INBX
Inhibrx Biosciences Inc
 May 16, 2026 BUY Strong Buy
+186.1% avg upside
5 analysts
$230.00
137.11% Upside
 -15.5% ·
🔒 3 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Oliver McCammon — Frequently Asked Questions
How accurate are Oliver McCammon's stock ratings?
Based on the calls 13Foresight could measure, about 44% of Oliver's ratings were profitable over a one-year hold, with an average return of +2.5% per rating, or +0.3% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Oliver ranked on 13Foresight?
Oliver McCammon is currently ranked #1731 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Oliver cover?
Oliver most recently has ratings on AURA, CATX, CRBP, JANX, GLUE, CELC, CADL, INBX. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.